The Next Hurdle

The Next Hurdle

Saying that Medtronic (NYSE: MDT) diabetes is on a roll is like saying the Chicago Cubs had a good year in 2016. Just as the Cubs have climbed the championship mountain and are now seeking another title, Medtronic continues to power ahead expanding their already large lead in the insulin pump market. Looking at the results reported this morning there is no question the recently approved 670G is not just positively impacting results but is adversely impacting everyone else in the space . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.